Possible risks and precautions of long-term use of Fenelidone (Keshenda)

Finerenone (Finerenone) is an oral non-steroidal selective mineralocorticoid receptor antagonist (MRA). It is mainly used for cardiorenal protective treatment in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus. Compared with traditional steroids MRA, while inhibiting mineralocorticoid receptors, fenelinone has a relatively low impact on hyperkalemia and renal function. However, long-term use may still have certain risks, and patients and doctors need to pay close attention.

First, one of the major risks of long-term use of fenelinone is hyperkalemia. Mineralocorticoid receptor antagonists decrease sodium reabsorption and potassium excretion, which may result in an increase in serum potassium. Hyperkalemia can cause cardiac arrhythmia, which may even be life-threatening in severe cases. Clinical studies have shown that some patients who take fenelidone for a long time develop mild or moderate hyperkalemia. Therefore, patients need to monitor their serum potassium levels regularly during medication, especially those with decreased renal function or those taking other potassium-raising drugs (such as ACE inhibitors, ARB, and some diuretics).

Secondly, fenelinone may have a certain impact on renal function. Although it is less renally toxic than traditional MRA, it may still cause an increase in serum creatinine or a decrease in glomerular filtration rate (eGFR). Especially in patients with basic renal insufficiency, long-term medication may increase the risk of acute kidney injury. Therefore, patients should conduct a detailed renal function assessment before using fenelidone, and regularly follow up renal function indicators during treatment. The dose should be adjusted in a timely manner or the drug should be temporarily discontinued according to changes to ensure safety.

In addition, long-term use of fenelidone may be associated with adverse reactions such as hypotension, fatigue, and dizziness. Some patients may experience a mild drop in blood pressure at the beginning of treatment, which is particularly important for patients taking antihypertensive drugs concomitantly. Patients should pay attention to prevent dizziness or falling when getting up or changing position, and avoid adjusting the drug dosage on their own. For patients who experience obvious symptoms of discomfort, their doctors should be informed promptly so that necessary supportive treatment can be taken or the medication regimen can be adjusted.

Considerations for long-term use of fenelidone also include individualized management and evaluation of concomitant medications. Patients should maintain close communication with their doctors during medication, regularly review key indicators such as serum potassium, renal function, and blood pressure, and follow the doctor's guidance for dosage adjustments. For patients with concomitant heart failure, hypertension, or other cardiorenal protective medications, the risk of drug interactions should be assessed to avoid adverse events. At the same time, patients should maintain a healthy lifestyle, including a reasonable diet, controlling potassium intake, and maintaining moderate exercise, which will help reduce the risks of long-term medication and improve the benefits of treatment.

In short, fenelinone is a new non-steroidal drugMRA, plays an important role in chronic kidney disease and cardiovascular protection, but long-term use still requires attention to risks such as hyperkalemia, changes in renal function, and blood pressure fluctuations. Through strict monitoring, individualized dose adjustment and lifestyle management, patients can obtain the cardio-renal protective effects of fenelidone while minimizing risks, and achieve safe and standardized long-term treatment.

Reference link:https://www.drugs.com